News
AI is reshaping life sciences. Learn how compliant, explainable, and genuinely useful systems move from pilot to scale and ...
Irish-made medicines heading to the US face steep new duties, raising alarm among patients, producers and investors on both ...
Novo keeps China manufacturing investments rolling with $112M for new quality testing lab in Tianjin
A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back ...
Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada ...
The symptoms can include nerve pain, emotional numbness and sexual dysfunction and can last for years after stopping the ...
A GLP-1/glucagon dual agonist conferred weight loss of up to 12.55% at 32 weeks for adults with overweight or obesity, ...
4h
Stocktwits on MSNEli Lilly’s Alzheimer’s Drug Gets US FDA Label Update For More Gradual Dosing After Study Shows Reduced Side EffectsEli Lilly and Company (LLY) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved a label ...
A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...
President Trump has threatened to slap a 200% tariff on foreign-made pharmaceuticals. That would roil the $200 billion-plus ...
The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...
The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA approves a ...
The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results